NKTR is a bio-pharmaceutical company that has a large pipeline.
News:
July 25th FDA issues letter postponing a Advisory Committee meeting (ADCOM) on their pain relief drug, the postponement is not related to the specific drug itself price drops.
Aug 1st: Breakthrough Therapy Designation given for metastatic melanoma drug
Aug 8th Earnings Report - expect a sell off at ER based on coming week's action. Could be a good time to load up before PDUFA
Aug 29: PDUFA still scheduled.
My Plan:
Basically NKTR got hit with a letter from the FDA knocking it out of it's triangle. Now with good news about the Breakthrough therapy designation it is possibly taking back lost ground. This could be a good chance to get in this company before the Aug 29 PDUFA.
Warning: Biotech stocks have high volatility and are unpredictable which is the nature of the biotech market. Please trade at your own risk. This is just an idea.